{"id":10348,"date":"2021-06-11T11:26:12","date_gmt":"2021-06-11T18:26:12","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10348"},"modified":"2021-06-15T11:27:02","modified_gmt":"2021-06-15T18:27:02","slug":"first-dose-chadox1-and-bnt162b2-covid-19-vaccines-and-thrombocytopenic-thromboembolic-and-hemorrhagic-events-in-scotland","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/11\/first-dose-chadox1-and-bnt162b2-covid-19-vaccines-and-thrombocytopenic-thromboembolic-and-hemorrhagic-events-in-scotland\/","title":{"rendered":"First-Dose ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic and Hemorrhagic Events in Scotland"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Compared to those who received one dose of the Pfizer-BioNTech COVID-19 vaccine, receipt of one dose of the Oxford-AstraZeneca vaccine was associated with a higher risk of\u00a0idiopathic thrombocytopenic purpura (ITP), a blood disorder involving low platelet counts, during 0\u201327 days after vaccination (adjusted RR = 5.8), with an estimated incidence of 1.13 cases per 100,000 doses. Findings were based on a nested, incident-matched case-control study (N=2.5 million) conducted in Scotland. Confirmatory self-controlled case series analysis confirmed this association was unlikely to be due to bias, although the true risk ratio is likely lower (RR=1.2) due to the potential for overestimation of reported results due to residual confounding. Receipt of the Pfizer-BioNTech vaccine was not associated with ITP. The authors suggest that using an alternative to the AstraZeneca vaccines may be appropriate for individuals at low risk of COVID-19 if supply allows.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Simpson et al. (June 2021). First-Dose ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic and Hemorrhagic Events in Scotland. Nature Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1038\/s41591-021-01408-4\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1038\/s41591-021-01408-4<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Compared to those who received one dose of the Pfizer-BioNTech COVID-19 vaccine, receipt of one dose of the Oxford-AstraZeneca vaccine was associated with a higher risk of\u00a0idiopathic thrombocytopenic purpura (ITP), a blood disorder involving low platelet counts, during 0\u201327 days after vaccination (adjusted RR = 5.8), with an estimated incidence of 1.13 cases per 100,000&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/11\/first-dose-chadox1-and-bnt162b2-covid-19-vaccines-and-thrombocytopenic-thromboembolic-and-hemorrhagic-events-in-scotland\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[41,34],"topic":[31],"class_list":["post-10348","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-children","tag-clinical-characteristics","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10348"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10348\/revisions"}],"predecessor-version":[{"id":10349,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10348\/revisions\/10349"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10348"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}